Leader Co.
This article was originally published in The Tan Sheet
Executive Summary
In April 21 warning letter, FDA states the company's aloe vera gel is an unapproved new drug because it is marketed with claims that refer to disease including "irritable bowel syndrome, antibacterial, anti-pruritic, arthritis, athlete's foot, boils, chicken pox, cold sores, colitis, ear infection, eczema, fever blisters, fungicidal, gastritis, hemorrhoids, psoriasis, skin rashes, tonsilitis, ulcers, vaginitis, virucidal." Based in North Canton, Ohio, the company markets the product through mail order. Leader Co. is developing its response to the letter
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning